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Abstract: Sub-lethal doses of radiation can modulate gene expression, making tumor cells more
susceptible to T-cell-mediated immune attack. Proteasome inhibitors demonstrate broad anti-tumor
activity in clinical and pre-clinical cancer models. Here, we use a combination treatment of proteasome
inhibition and irradiation to further induce immunomodulation of tumor cells that could enhance
tumor-specific immune responses. We investigate the effects of the 26S proteasome inhibitor,
bortezomib, alone or in combination with radiotherapy, on the expression of immunogenic genes
in normal colon and colorectal cancer cell lines. We examined cells for changes in the expression
of several death receptors (DR4, DR5 and Fas) commonly used by T cells for killing of target cells.
Our results indicate that the combination treatment resulted in increased cell surface expression of
death receptors by increasing their transcript levels. The combination treatment further increases
the sensitivity of carcinoma cells to apoptosis through FAS and TRAIL receptors but does not
change the sensitivity of normal non-malignant epithelial cells. Furthermore, the combination
treatment significantly enhances tumor cell killing by tumor specific CD8+ T cells. This study
suggests that combining radiotherapy and proteasome inhibition may simultaneously enhance tumor
immunogenicity and the induction of antitumor immunity by enhancing tumor-specific T-cell activity.
Keywords: radiation; proteasome; death receptors; anti-tumor immunity

1. Introduction
Colorectal cancer (CRC) is the third most common cancer type and the five year survival rate
is less than 30% for advanced colorectal cancer [1]. Immunotherapies offer a promising modality
for the treatment of advanced cancers because the immune system is systemic and thus able to
attack metastatic disease [2,3]. Tumor-specific cytotoxic T lymphocytes (CTLs) and activated natural
killer (NK) cells play particularly important roles in cancer cell killing and are the basis of many
immunotherapies [4,5].
One way to improve tumor cell killing by CTLs or NK cells is to enhance expression of death
receptors on tumor cells. DR4 (TRAIL-R1), DR5 (TRAIL-R2) and Fas (CD95/Apo-1) are members of the
tumor necrosis factor receptor superfamily (TNFRSF), and ligation of death receptors by binding with
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cognate death ligands from anti-tumor immune cells induces apoptotic signals into tumor cells [6].
Fas is the complementary receptor for Fas-ligand (FasL) and this interaction plays an important role
in triggering apoptosis. During cancer progression, the interaction between Fas and FasL is largely
impaired due to suppression of Fas expression on tumor cells [7–9]. DR4 and DR5 are receptors for
the tumor necrosis factors-related apoptosis-inducing ligand (TRAIL) and they are also essential for
driving apoptosis in many types of tumor cells [10]. TRAIL is highly expressed in NK cells and CD8+ T
cells [11], and it is part of a natural mechanism to kill tumor cells by the immune system and selectively
induces apoptosis in cancer cells with less toxicity towards healthy/non-cancerous cells [12]. However,
tumor cells often down-regulate cell surface expression of death receptors in order to avoid elimination
by immune cells [13,14]. Thus, enhancing the expression of these death receptors on cancer cells could
increase tumor cell sensitivity to CTL-mediated killing.
We have shown that sub-lethal doses of radiation can modulate gene expression, making
tumor cells more susceptible to immune responses including enhancing T-cell-mediated immune
attack [15–17]. While radiation is a useful tool to make tumor cells more susceptible to immune
cells [18], effective immunotherapy approaches need to be developed for the treatment of multiple
advanced cancer types. The 26S proteasome is a large protein complex formed by 19S regulatory and
20S core subcomponents, and found in the nucleus and cytoplasm of eukaryotic cells [19]. The 26S
proteasome is the main non-lysosomal protein degradation machinery and inhibition of the 26S alters
protein turnover and impacts cellular homeostasis [20]. Inhibition of the 26S also alters expression
of numerous target genes at the transcriptional level by increasing the stability of transcription
factors and/or epigenetic modifiers [21,22]. Bortezomib is the first FDA approved 26S proteasome
inhibitor and is currently used for the treatment of multiple myeloma and mantle cell lymphoma [23].
Bortezomib specifically inhibits the chymotrypsin-like activity of the 26S [24].
It has been reported that bortezomib sensitizes melanoma tumors to dendritic cell-activated
immune responses [25] and to TRAIL-mediated apoptosis [26,27]. Recent clinical trials demonstrate
the feasibility of using bortezomib concurrently with carboplatin/paclitaxel and radiation in non-small
cell lung cancer [28], and the combination of histone deacetylase and proteasome inhibitors was shown
to enhance CD8+ T cell responses in a preclinical cervical cancer model [29]. However, it remains
unclear if the combination of radiation and proteasome inhibition alters immune responses against
tumors. Here we hypothesize that a combination treatment of sub-lethal radiation and bortezomib
will increase expression of death receptors in CRC cells, which will make these cancer cells more
susceptible to death-receptor mediated cell killing, and will enhance the CTL-mediated anti-tumor
immune attack. Our specific goal is to increase expression of death receptors in CRC cells by a
combination of sub-lethal radiation and inhibition of the 26S proteasome to enhance CTL-mediated
tumor killing. Our data demonstrate that a combination of 26S proteasome inhibition and sub-lethal
radiation significantly increases the sensitivity of carcinoma cells, but not normal non-malignant
epithelial cells, to apoptosis. Combination treatment increases cell surface expression of multiple death
receptors by increasing transcriptional activation of each gene. Our studies suggest that combining
radiotherapy and proteasome inhibition may simultaneously enhance tumor immunogenicity and the
induction of antitumor immunity by enhancing tumor-specific T-cell activity.
2. Results
2.1. Effects of Combination Treatment on Colorectal Cancer Cell Viability
To investigate the effects of the 26S proteasome inhibitor bortezomib, in combination with
radiotherapy, on tumor cell death we used two well characterized colorectal cancer cell lines (SW620
and HCT116). The tumor cells were mock-irradiated (0 Gy) or irradiated with 5 Gy and were re-cultured
for 24 h. Following incubation, mock-irradiated or irradiated cells were treated with 10 nM bortezomib
and were incubated for an additional 24 h. Cell viability was detected based on Annexin V and 7 AAD
staining (Figure 1). Flow cytometric analysis was used to distinguish between populations of live
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2.4. Combination Treatment with Bortezomib and Radiation Up-Regulates Cell Surface Protein Expression of
Death Receptors in Tumor Cells
Next, to determine if combination treatment of proteasome inhibition and sub-lethal radiation
could synergize to alter protein expression of DR4, DR5 and Fas, we investigated cell surface expression
of these death receptors following treatment of non-malignant and malignant cells. Normal CCD-18Co
colon fibroblast cells expressed low level of DR4 without treatment and the surface expression slightly
increased with IR treatment but was never detected in greater than 20% of the normal cells. Untreated
CCD-18Co colon cells expressed high levels of DR5 and Fas on the surface, but neither radiation
nor bortezomib treatment significantly altered DR5 or Fas surface expression on CCD-18Co cells
(Figure 4A). In contrast to CCD-18 Co cells, both individual treatments and the combination treatment
significantly increased cell surface protein expression of DR4, DR5 and Fas in both colorectal carcinoma
cell lines (Figure 4B,C). High levels of DR5 surface expression on untreated SW620 and HCT116,
and Fas surface expression on HCT116 cells, make it difficult to see changes in the frequency of cells
expressing these receptors. However, changes in the median fluorescence intensity (MFI) values
reveal a substantial change in the expression (density) levels of both DR5 and Fas following radiation,
bortezomib or combination treatment (Figure 4C; insets). Representative FACS plots show that the
treatments modulate expression of death receptors only in malignant tumor cells, not in normal
colon cells and the better increase in the expression of these death receptors was observed with the
combination treatment in SW620 and HCT116 malignant cells (Figure 4D–F). Consistent with mRNA
expression data, the combination treatment had a considerable impact on protein expression of death
receptors in both tumor cells as compared to untreated cells. In contrast, irradiation and inhibition
of the 26S proteasome did not impact the near normal cell line. Overall, these data suggest that the
combination treatment had little impact on the expression of death receptors in normal colon cell line
but significant effect on expression of these proteins in colorectal cancer cells.
2.5. Proteasome Inhibition Can Further Increase Radiation-Induced Sensitivity to Killing of CRC Cells by CD8+
T Cells
To test if the combination treatment enhances colorectal cancer cell sensitivity to CTLs, SW620 cells
were irradiated (5 Gy) or treated with combination irradiation plus bortezomib prior to incubation with
carcinoembryonic antigen (CEA)-specific CD8+ T cells. The level of active caspase-3 was evaluated
in tumor cells by flow cytometry after co-culturing with CEA specific CTLs as a measure of cells
undergoing caspase-dependent cell death. Tumor cells displayed significantly increased levels
of caspase-3 after irradiation (21.0%) and combination treatment with irradiation and bortezomib
(37.5%) following incubation with tumor-specific T cells (Figure 5A). The combination treatment
resulted in higher killing than radiation treatment alone. In the absence of CEA specific T cells the
caspase-3 expressions was low after each of the different treatments (control—4.66%, 5 Gy—7.4%,
combination—15.8%; Figure 5B) similar to the low levels of cell death seen by Annexin-V and 7AAD
viability analysis (Figure 1). Background subtracted values from the average of three independent
experiments show that radiation (12.3%) and the combination (17.6%) treatment greatly increase
tumor-specific T cell activity against tumor cells (Figure 5C,D). Thus, these data suggest that colorectal
carcinoma cells treated with combination irradiation and bortezomib are even more sensitive to killing
mediated by tumor antigen specific T cells than tumor cells treated with radiation alone.
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radiation on gene expression that mediates immune mediated apoptosis. Our work significantly
contributes to the cancer immunotherapy field by using the combination of sub-lethal radiation and
proteasome inhibitor in controlling the expression of death receptors on tumor cells for sensitivity to
cytolysis by CTLs. In this study, we show that the combination treatment of bortezomib and sub-lethal
radiation significantly increases the cell surface expression of multiple death receptors by increasing
their transcriptional abundance and surface expression.
We started to investigate the effects of the 26S proteasome inhibitor, bortezomib, alone or in
combination with radiotherapy, on direct induction of cell death in two colorectal cancer cell lines.
We found that the level of radiation utilized in these experiments is sub-lethal and the bortezomib
concentration is very lowly lethal in colorectal cancer cell lines. Despite an increase in cell death with
the combination treatment, over 80% of tumor cells remain viable (Figure 1). We also evaluated the
possibility of an impairment in the initial DNA damage response as a potential mechanism for the
increase in apoptosis. No difference in the extent of DNA damage was observed after the addition of
bortezomib to radiation (Figure 2) indicating that the DNA damage response is not inhibited by the
combination treatment and therefore not likely to be the cause of the increased apoptosis.
It has been shown that ionizing radiation effects proteasome structures [40] but the dynamics of the
induction of proteasome inhibitor in irradiated cells is unclear, and the role of proteasome inhibition
in expression of death receptors in response to radiation has not been investigated. Treatments
significantly increased the transcript expression of DR4, DR5 and Fas in colorectal tumor cells (Figure 3).
Interestingly, we did not see any alteration in the transcript expression of death receptor in normal
colon CCD-18Co cell line. Consistent with mRNA data, individual treatments or the combination
treatment significantly increase cell surface protein expression of DR4, DR5 and Fas in both colorectal
carcinoma cell lines (Figure 4).
One of the most effective cancer immunotherapy strategies is to generate tumor-associated antigen
(TAA) specific CTLs that are capable of killing tumor cells [41–43]. TAAs are derived from normal
cellular proteins that have been mutated or are overexpressed by tumor cells [44]. For example,
carcinoembryonic antigen (CEA) peptide is highly expressed in several cancer types, including CRC,
and the immune system is not tolerant to these tumor-derived antigens [45]. The generation of CEA
specific CTL responses in human has been under investigation in clinical trials for several cancer
types [46–48]. Thus, enhancing tumor cell recognition by CTLs could increase tumor killing rate by
TAA specific CTLs. Our results demonstrate that bortezomib and sub-lethal irradiation dramatically
enhanced the percentage of SW620 colorectal cancer cells killed by CEA-specific T cells and the
combination treatment further increased the percentage of apoptotic cells upon interaction with T
cells (Figure 5). These data suggest that sub-lethal radiation or proteasome inhibition sensitize tumor
cells to death-receptor mediated apoptosis, possibly through upregulation of death receptors, which
sensitizes tumor cells to CTL-mediated killing.
Activation of caspase-3 is known as the endpoint of the caspase cascade that facilitates
apoptosis [49]. Thus, we measured the frequency of cells with active caspase-3 to identify the number
of apoptotic cells following treatment with anti-Fas or recombinant TRAIL protein to test if enhanced
expression of death receptors by irradiation and bortezomib treatment would in fact increase sensitivity
to killing through FasL or TRAIL receptors in tumor cells. Our data indicate that bortezomib and
sub-lethal irradiation did not sensitize normal colon CCD-18Co cells to killing by anti-Fas (Figure 6A).
However, irradiation itself or with combination of bortezomib significantly sensitized HCT116 cells
to killing by anti-Fas (Figure 6C). Consistent with previous data, none of the treatments sensitized
SW620 cells to killing by anti-Fas [15,32] (Figure 6B). SW620 cells have acquired genetic defects in
apoptotic pathways and thus are resistant to FAS mediated apoptosis, which could be a potential
mechanism of how some colon cancer cells escape the immune system. Importantly, these cells were
still killed better by T cells suggesting that they can be rendered sensitive to attack when modulated
by radiation and bortezomib. TRAIL selectively induces apoptosis in tumor cells by binding both
DR4 and DR5 death receptors [50]. Our results show that bortezomib and sub-lethal irradiation did
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not sensitize CCD-18Co cells to killing by TRAIL (Figure 6A). However, the treatments significantly
enhanced the percentage of active caspase-3 in both colorectal cancer cell lines (Figure 6B,C). Despite
having defects in FAS-mediated apoptosis, SW620 cells were sensitized to TRAIL-mediated apoptosis
following radiation, bortezomib and the combination treatment.
Consistent with previous studies, bortezomib treatment did not alter expression of death receptors
in normal colon cells [51], which suggest that bortezomib has tumor selectivity. It is unclear why
normal cells show less response to bortezomib treatment, but this could be because tumor cells require
more protein synthesis which increases their dependency on proteasomal degradation. Furthermore,
we didn’t see much change in FAS and TRAIL induced apoptosis in normal cells following bortezomib
or radiation treatment (Figure 6A). Conversely, tumor cells were much more sensitive than normal
cells to proteasome inhibition and radiation treatment. Differences in sensitivity to TRAIL also do
not correlate obviously with variable p53 status or tumor grade between the cell lines [52–54]. Thus,
it could be due to a loss of checkpoint mechanisms in cancer cells; however further investigation needs
to be done to clarify the issue.
Our findings suggest that a combination treatment of radiation and bortezomib can be used
for the treatment of colorectal cancer by inducing increased sensitivity to tumor specific immune
responses. Having sufficient expression of death receptors on tumor cells may enhance the ability
of tumor-specific T-cell activity and sensitivity to tumor cells. Radiation has been commonly used
for the treatment of several cancers [55,56] and proteasome inhibitors demonstrate broad anti-tumor
activity in clinical and pre-clinical cancer models [36,57]. Combination of radiation and proteasome
inhibition maybe usefully applied in combination with immunotherapy to enhance T cell reactivity
against tumors. In the last decade, many studies of immunotherapy for the treatment of malignant
cancers have brought new strategies and approaches for improving the prognosis of cancer. Thus, our
findings further contribute to our understanding of how clinically approved agents may be used to
enhance immunotherapy strategies for the treatment of advanced colorectal cancer.
4. Experimental Section
4.1. Reagents and Cell Lines
Bortezomib were purchased from LC Laboratories (Woburn, MA, USA). Colorectal tumor cell line
HCT116 cells were generously provided from the Laboratory of Tumor Immunology and Biology, NCI,
NIH. Human colorectal carcinoma cell line SW620 and near normal CCD-18Co cells were purchased
from ATCC. All cells were cultured in media designated by ATCC for propagation and maintenance.
Cells were incubated at 37 ˝ C incubator with 5% CO2 and tested to ensure absence of Mycoplasma.
4.2. Irradiation
Tumor and normal cells were irradiated by using a RS-2000 biological X-ray irradiator (Rad source
technology, Suwanee, GA, USA). Cells were irradiated at a dose rate of 2 Gy/min for 2.5 min by setting
irradiator voltage and current at 160 kV and 25 mA. During irradiation, the cells were maintained in
recommended media and kept on ice. Following irradiation, the culture media was replaced with the
fresh media.
4.3. Apoptosis Assay
Apoptosis of tumor cells was assessed using the Annexin V-PE Apoptosis Detection Kit I Tumor
cells were mock-irradiated (0 Gy) or irradiated with 5 Gy and re-cultured for 24 h. Following incubation,
mock-irradiated or irradiated cells were treated with 10 nM bortezomib and incubated for an additional
24 h. The tumor cells were briefly trypsinized and harvested. The cells were then washed with cold
PBS twice and resuspended in Annexin V binding buffer at a concentration of 1 x 106 cells/mL.
Cells were then transferred to 5 mL culture tubes containing 5 µL of Annexin V-PE and/or 5 µL of
7-Aminoactinomycin D (7-AAD). The samples were gently mixed and were incubated for 20 min
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at room temperature. Following the addition of 400 µL of Annexin V binding buffer to each tube,
samples were analyzed and quantified by flow cytometry and resulting data were analyzed using
FlowJo software. Viable cells were negative for both annexin V-PE and 7-AAD; early apoptotic cells
were positive for annexin V-PE and negative for 7-AAD, whereas late apoptotic and dead cells were
positive for both annexin V-PE and 7-AAD labeling.
4.4. Comet Assay
The extent of DNA damage and resulting DNA damage repair was assessed using single cell
gel electrophoresis (Comet assay) under alkaline conditions. Briefly, SW620 cells were plated and
cultured for 24 h, then treated or not treated with bortezomib and incubated for an additional 24 h.
The tumor cells were rinsed with PBS to remove dead cells, briefly trypsinized, harvested, and
gently resuspended in fresh media. Tumor cells were then mock-irradiated (0 Gy) or irradiated with
10 Gy and immediately placed on ice or allowed to incubate at room temperature for 20 min and
then placed on ice. Approximately 1 ˆ 104 cells were gently mixed with previously melted 0.5%
low-melting agarose in PBS at 37 ˝ C, applied to a slide previously coated with 1% normal-melting
agarose, allowed to solidify in a cold box, and then immediately placed in lysis buffer (2.5 M NaCl,
100 mM EDTA, 10 mM Tris, 0.02% Triton, pH 10). Following lysis, the slides were placed in an alkaline
solution (300 mM NaOH, 1 mM EDTA) for 30 min and subjected to electrophoresis in alkaline solution
for 30 min (33 V, 300 mA). Following electrophoresis, slides were washed 4 times with cold H2 O,
DNA was precipitated with cold 100% ethanol for 5 min, and slides were allowed to dry at room
temperature overnight. The resulting gels were stained using Sybr Green I and visualized using an
LSM 700 scanning confocal microscope. Comet images were analyzed with the OpenComet algorithm
(v 1.3) [58]. Late apoptotic cells present a different profile in the comet assay due to the degradation
of genomic DNA (a characteristic “hedgehog” shape with a small head and a large “fan like” tail);
these profiles were not included in the assay. The Olive tail moment was used for analysis: Olive Tail
moment = (Tail Mean — Head Mean) ˆ % DNA in Tail/100. Statistical analysis was performed using
GraphPad (GraphPad Software, Inc., La Jolla, CA, USA).
4.5. RNA Expression and Quantitative Real-Time PCR
mRNA was isolated using QIAzol RNA extraction reagent (Qiagen) as described in
Cacan et al. [59]. Briefly, cells were lysed in QIAzol and agitated on a 3D rotator for 5 min. Two
hundreds µL of chloroform was added and was incubated for 3 min at room temperature. Samples
were centrifuged and the aqueous phase was transferred to an eppendorf tube. Five hundreds µL of
isopropanol was added and was incubated for 10 min at room temperature. Following centrifugation,
pellets were washed with 75% cold ethanol, centrifuged and resuspended in RNAse free water. RNA
was quantified and cDNA was generated from 1 µg of total extracted RNA using an Omniscript Reverse
Transcription Kit (Qiagen, Valencia, CA, USA). Following cDNA synthesis, quantitative real-time
polymerase chain reaction was performed using TaqMan Universal PCR Master Mix (Qiagen) and
specific primers and probes targeting gene of interest (Applied Biosystems; Fas/CD95; Hs00163653_m1,
DR4/TNFRSF10A; Hs00269492_m1, DR5/TNFRSF10B; Hs00366278_m1 and HPRT1; Hs99999909)
according to manufacturer’s protocol. Transcript expression was assessed using an ABI prism 7900HT
Real-Time PCR System (Applied Biosystems, Carlsbad, CA, USA). Reactions were normalized against
HPRT1 expression and calculations were performed using standard curves generated.
4.6. Cell Surface Staining and Flow Cytometry Analysis
Cell surface staining of tumor and normal cells were performed using the following primary
labeled antibodies; Fas-PE, DR4-PE, DR5-APC and the appropriate isotype matched controls
(BioLegend. San Diego, CA, USA). Surface staining was performed in cell staining buffer for 45 min on
ice. Stained cells were acquired on a BD Fortessa flow cytometer. Dead cells were excluded from the
analysis based on scatter profile. Isotype control staining was less than 5% for all samples analyzed.
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4.7. CTL Killing Assay
Peripheral blood mononuclear cells (PBMCs) from HLA-A2+ donors were purchased from
Hemacare (Van Nuys, CA, USA) for generation of antigen specific CTLs. PBMCs were cultured
in AIM-V media (Life Technologies, Carlsbad, CA, USA) for 2 h to allow them to adhere to the culture
flask. Non-adherent cells were removed for lymphocyte isolation. Adherent cells were cultured for
a week in the presence of 100 ng/mL of human granulocyte-macrophage colony stimulating factor
(GM-CSF) and 20 ng/mL of IL-4 (Miltenyi Biotec, Inc. Auburn, CA, USA) to induce dendritic cell
differentiation. On day five, 500 ng/mL of CD40L (Millipore) were added to mature the dendritic
cells (DC). On day seven, DCs were harvested and 1 ˆ 105 of DCs were plated in a 12-well plate
and then were pulsed with 40 µg/mL of HLA-A2 binding CEA peptide (YLSGANLNL) for 4 h in
37 ˝ C. CEA loaded DCs were irradiated with 50 Gy to inhibit DCs proliferation and processing of
new antigens. CD8+ T cells were isolated from non-adherent PBMCs using immunomagnetic beads
(Miltenyi Biotec Inc., Auburn, CA, USA), as described by the manufacturer. Isolated CD8+ T cells
were co-cultured with peptide loaded DCs in the presence of 10 ng/mL of IL-7 and 30 U/mL of
IL-2 (Millipore, Temecula, CA, USA) to promote T cells viability and clonal expansion. IL-7 and IL-2
were refreshed on the third day. T cells were re-stimulated every 7-days with freshly pulsed DCs
and peptide as described above. After three in vitro stimulations T cells were isolated over ficoll and
used for caspase-dependent killing assays. SW620 cells were treated with IR (5 Gy), bortezomib or
combination of irradiation and bortezomib. After 48 h irradiation and 24 h bortezomib treatment,
the tumor cells were harvested and co-cultured with CEA specific CTLs (E:T ratio 10:1) at 37 ˝ C
for 3.5 h. After co-incubation, tumor cells were harvested and stained with EpCAM (Epithelial cell
adhesion molecule; Miltenyi Biotech, San Diego, CA, USA) followed by intracellular staining with
active caspase-3 (BD PharMingen, San Diego, CA, USA).
4.8. Functional Death Receptor Assay
Cells were mock-irradiated (0 Gy) or irradiated with 5 Gy and re-cultured for 24 h. Following
incubation, mock-irradiated or irradiated cells were treated with 10 nM bortezomib and incubated
for an additional 24 h. The cells were harvested and counted. Cells were then incubated for 3 h with
varying concentrations of agonistic anti-Fas antibody, clone CH11 (MBL, Watertown, MA, USA) or
recombinant TRAIL protein (Millipore, Billerica, MA, USA). Control cells were incubated with IgM
isotype control antibody (BD Biosciences, San Diego, CA, USA). Cells were subsequently fixed and
permeabilized before being stained for intracellular active caspase-3 with a PE-labeled monoclonal
antibody (BD Biosciences San Diego, CA, USA). Stained cells were acquired on a BD Fortessa flow
cytometer (BD PharMingen, San Diego, CA, USA). The level of activated caspase-3 was quantified by
flow cytometry, as described above.
4.9. Statistics
Results were statistically evaluated using Student paired t test. The p values <0.05 are indicated
by one asterisk (*). The p values <0.005 are indicated by two asterisks (**). The p values <0.0005 are
indicated by three asterisks (***).
5. Conclusions
This study suggests that the combination of radiation and the proteasome inhibitor, bortezomib,
may simultaneously enhance tumor immunogenicity and the induction of antitumor immunity by
enhancing tumor-specific T-cell activity and sensitivity to death receptor mediated apoptosis. Findings
in the manuscript indicate that combined treatment of bortezomib and radiation can be used as a
potential therapeutic regimen for the treatment of advanced colorectal cancer with limited toxicity to
normal non-malignant cells.
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